Dongcheng Biochem's subsidiary has received the drug clinical trial approval notice
I'm PortAI, I can summarize articles.
Dongcheng Biochem's subsidiary LNC PHARMA PTE. LTD. has received FDA approval to conduct Phase I clinical trials for the 225Ac-LNC1011 injection. The FDA has completed the safety review of the drug and believes that clinical research for prostate cancer can continue. After receiving approval, the drug still needs to complete clinical trials and pass FDA review before it can be marketed in the United States
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments